Friday 20 March 2026
Internal Reference Number: FOI_9185
Date Request Received: 27/01/2026 00:00:00
Date Request Replied To: 11/02/2026 00:00:00
This response was sent via: By Email
Request Summary: Treatment of Chronic Lymphocytic Leukaemia (CLL)
Request Category: Researcher
| Question Number 1: How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to? | |
| Answer To Question 1: 58 patients | |
| Question Number 2: How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments: • BR (bendamustine + rituximab) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Calquence (acalabrutinib) + Gazyva (obinutuzumab) • Calquence (acalabrutinib) + Venclyxto (venetoclax) • Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab) • FCR (fludarabine + cyclophosphamide + rituximab) • Fludarabine Monotherapy • Gazyva (obinutuzumab) + chlorambucil • Imbruvica (ibrutinib) • Venclyxto (venetoclax) • Venclyxto (venetoclax) + Gazyva (obinutuzumab) • Venclyxto (venetoclax) + rituximab • Zydelig (idelalisib) + rituximab • Imbruvica (Ibrutinib) +Venclyxto (venetoclax) • Any other systemic anti-cancer therapy | |
| Answer To Question 2: BR (bendamustine + rituximab) 0 • Brukinsa (zanubrutinib)16 • Calquence (acalabrutinib) 16 • Calquence (acalabrutinib) + Gazyva (obinutuzumab) 0 • Calquence (acalabrutinib) + Venclyxto (venetoclax) 0 • Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab) 0 • FCR (fludarabine + cyclophosphamide + rituximab) 0 • Fludarabine Monotherapy 0 • Gazyva (obinutuzumab) + chlorambucil 0 • Imbruvica (ibrutinib) 5 • Venclyxto (venetoclax) <5 • Venclyxto (venetoclax) + Gazyva (obinutuzumab) 7 • Venclyxto (venetoclax) + rituximab <5 • Zydelig (idelalisib) + rituximab 0 • Imbruvica (Ibrutinib) +Venclyxto (venetoclax) 7 • Any other systemic anti-cancer therapy <5 | |
| Question Number 3: How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following: • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Imbruvica (ibrutinib) • Venclyxto (venetoclax) • Zydelig (idelalisib) + rituximab • Any other systemic anti-cancer therapy | |
| Answer To Question 3: Brukinsa (zanubrutinib) <5 • Calquence (acalabrutinib) 0 • Imbruvica (ibrutinib) <5 • Venclyxto (venetoclax) <5 • Zydelig (idelalisib) + rituximab 0 • Any other systemic anti-cancer therapy <5 | |
| Question Number 4: If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials. | |
| Answer To Question 4: The Trust is participating in 1 Clinical Trials for the treatment of CLL. IRAS 126738 is closed to recruitment but currently in follow up. IRAS 1003615 is currently open to recruitment. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
